L-093-2005

Agreement ID
L-093-2005
Lead IC
NIAID
Exclusivity
Exclusive
External Party
Janssen Vaccines & Prevention B.V.
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-2000     Recombinant Vaccines Based on Poxvirus Vectors
TAB-562     Vaccination Strategies to Provide Protection Against the Ebola Virus
TAB-1003     Accelerated Vaccination Strategies to Provide Protection Against Viral Infections